Fibrocell Reports 2017 Financial Results and Recent Highlights

Fibrocell Science (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the year ended December 31, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.

As quoted in the press release:

“We are pleased with the substantial progress of our gene therapy candidates that continues to advance and positions us to achieve important milestones in 2018,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “In January 2018, the U.S. Food and Drug Administration granted us allowance to enroll pediatric patients in the Phase 2 portion of our Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa, a key milestone for the program.”

Click here to read the full press release.